Researchers from Johns Hopkins University, Baltimore USA, presented findings at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January 2012 in San Franciso from a early phase (Phase 1b) trial of BioSante Pharmaceuticals' pancreatic cancer vaccine GVAX used in combination with an anticancer immunotherapy (Bristol Myers Squib's ipilimumab) in 30 patients who had previously-treated locally advanced or metastatic pancreatic adenocarcinoma. The combined therapy showed improved survival in addition to both therapies being be safe to use (the main purpose of the trial), which has led to the setting up of a larger muilti-centre study to start this year that should provide more definitive data on the improvement in survival. Pancreatic Cancer UK hopes that it may be possible for there to be a site for this trial in the UK.
For more information see http://www.biosantepharma.com/News-Rele ... ?ID=022712
This forum contains news that Pancreatic Cancer UK and forum users have shared over the years.
1 post • Page 1 of 1